AULSF (Austar Lifesciences) Beneish M-Score: -2.58 (As of Jun. 26, 2026)


AULSF Austar Lifesciences Ltd AULSF
49 GF Score
Price $0.07
GF Value $0.10
! 6 Warning Signs
View Full Analysis

What is Austar Lifesciences Beneish M-Score?

Austar Lifesciences AULSF 49 Beneish M-Score is -2.58 as of Jun. 26, 2026. GuruFocus rates AULSF with a GF Score™ of 49/100 and a GF Value™ of $0.10. The stock has 6 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Austar Lifesciences ranks worse than 50.65% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.58 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Austar Lifesciences's Beneish M-Score or its related term are showing as below:

AULSF' s Beneish M-Score Range Over the Past 10 Years
Min: -2.72   Med: -2.41   Max: -1.2
Current: -2.58

During the past 13 years, the highest Beneish M-Score of Austar Lifesciences was -1.20. The lowest was -2.72. And the median was -2.41.


Austar Lifesciences Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Austar Lifesciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Austar Lifesciences Beneish M-Score Chart

Austar Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.20 -1.56 -2.66 -2.72 -2.58

Austar Lifesciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.66 0.00 -2.72 0.00 -2.58

AULSF vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Austar Lifesciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Austar Lifesciences Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Austar Lifesciences's Beneish M-Score falls into.


AULSF
49GF Score
Austar Lifesciences Ltd AULSF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Austar Lifesciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Austar Lifesciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0222+0.528 * 1.0478+0.404 * 1.0193+0.892 * 1.0546+0.115 * 1.0022
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9225+4.679 * -0.046191-0.327 * 0.9922
=-2.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was $150.2 Mil.
Revenue was $217.3 Mil.
Gross Profit was $41.6 Mil.
Total Current Assets was $229.1 Mil.
Total Assets was $302.1 Mil.
Property, Plant and Equipment(Net PPE) was $46.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $7.0 Mil.
Selling, General, & Admin. Expense(SGA) was $31.9 Mil.
Total Current Liabilities was $168.7 Mil.
Long-Term Debt & Capital Lease Obligation was $10.4 Mil.
Net Income was $4.8 Mil.
Gross Profit was $0.0 Mil.
Cash Flow from Operations was $18.8 Mil.
Total Receivables was $139.3 Mil.
Revenue was $206.1 Mil.
Gross Profit was $41.4 Mil.
Total Current Assets was $213.1 Mil.
Total Assets was $286.2 Mil.
Property, Plant and Equipment(Net PPE) was $48.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $7.3 Mil.
Selling, General, & Admin. Expense(SGA) was $32.8 Mil.
Total Current Liabilities was $163.3 Mil.
Long-Term Debt & Capital Lease Obligation was $7.7 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(150.157 / 217.326) / (139.288 / 206.079)
=0.69093 / 0.675896
=1.0222

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(41.372 / 206.079) / (41.639 / 217.326)
=0.200758 / 0.191597
=1.0478

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (229.116 + 46.149) / 302.136) / (1 - (213.133 + 48.082) / 286.186)
=0.088937 / 0.087254
=1.0193

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=217.326 / 206.079
=1.0546

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(7.294 / (7.294 + 48.082)) / (6.983 / (6.983 + 46.149))
=0.131718 / 0.131427
=1.0022

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(31.944 / 217.326) / (32.837 / 206.079)
=0.146987 / 0.159342
=0.9225

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((10.433 + 168.684) / 302.136) / ((7.738 + 163.265) / 286.186)
=0.592836 / 0.597524
=0.9922

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(4.8 - 0 - 18.756) / 302.136
=-0.046191

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Austar Lifesciences has a M-score of -2.58 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.58 mean?
Austar Lifesciences (AULSF) has a Beneish M-Score of -2.58 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Austar Lifesciences and its competitors. According to the industry distribution chart, Austar Lifesciences ranks #388 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 50.7%.
Is Austar Lifesciences' Beneish M-Score too high?
Austar Lifesciences' current Beneish M-Score is -2.58. Based on the distribution chart, Austar Lifesciences ranks #388 out of 766 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Austar Lifesciences has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Austar Lifesciences ranks #388 out of 766 companies for Beneish M-Score. This places Austar Lifesciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Austar Lifesciences and its competitors. Austar Lifesciences's current Beneish M-Score is -2.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Austar Lifesciences (AULSF) has a current Beneish M-Score of -2.58. The stock's GF Value™ is $0.10, compared to a current price of $0.07 — trading 30% below its estimated fair value. The current Beneish M-Score is -2.58. Austar Lifesciences' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current Beneish M-Score is -2.58 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Austar Lifesciences (AULSF) Overvalued in 2026?

Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued. The current stock price of $0.07 is trading 30% below its estimated GF Value™ of $0.10.

Key valuation signals for AULSF:

  • Beneish M-Score: -2.58
  • GF Value™: $0.10 vs. price of $0.07 (30% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Austar Lifesciences Business Description

Other Exchanges 06118:Hong Kong
Address No.1018 Changning Road, Rooms 2010-2013, 20th Floor, Changning District, Shanghai, CHN
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
49GF Score

Get the complete analysis for AULSF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.07
Price
$0.10
GF Value